Attention is rising on whether the first immuno-onoclogy treatment option will be approved for endometrial cancer in Korea.

According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has passed review by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee and is soon to start drug pricing negotiations with the National Health Insurance Service.

The reimbursement process for the drug has been progressing relatively quickly since its approval in December, and as the drug seeks to be listed for a different indication from existing drugs, whether it will derive positive results is a focus of interest.

For the b